# Celcuity Inc.: financial statements, quarterly

CELC · Nasdaq · CIK 1603454 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/celc.md) · [Financials](/companies/celc/financials.md) · [Filings](/companies/celc/filings.md) · [Insiders](/companies/celc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/celc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [17.5](/filings/0001493152-24-046022.md) | [18.1 d](/filings/0001641172-25-001826.md) | [20.6](/filings/0001641172-25-011053.md) | [22.5](/filings/0001641172-25-024148.md) | [27.6](/filings/0001493152-25-022401.md) | [33.5 d](/filings/0001493152-26-012801.md) | [29.8](/filings/0001493152-26-023180.md) | [36.4](/filings/0001193125-26-349608.md) | [34.9](/filings/0001493152-25-022401.md) | [37.6 d](/filings/0001493152-26-012801.md) | [33.1](/filings/0001493152-26-023180.md) | [31.1](/filings/0001193125-26-349608.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [6.4](/filings/0001493152-26-023180.md) | [7.6](/filings/0001193125-26-349608.md) | not reported | not reported | [17.4](/filings/0001493152-26-023180.md) | [35.0](/filings/0001193125-26-349608.md) |
| Operating income | $m | [(18.9)](/filings/0001493152-24-046022.md) | [(19.7) d](/filings/0001641172-25-001826.md) | [(22.5)](/filings/0001641172-25-011053.md) | [(24.3)](/filings/0001641172-25-024148.md) | [(30.1)](/filings/0001493152-25-022401.md) | [(36.4) d](/filings/0001493152-26-012801.md) | [(36.1)](/filings/0001493152-26-023180.md) | [(44.0)](/filings/0001193125-26-349608.md) | [(42.8)](/filings/0001493152-25-022401.md) | [(49.2) d](/filings/0001493152-26-012801.md) | [(50.5)](/filings/0001493152-26-023180.md) | [(66.1)](/filings/0001193125-26-349608.md) |
| Interest expense | $m | [1.4](/filings/0001493152-24-046022.md) | [1.4 d](/filings/0001493152-24-011549.md) | [1.4](/filings/0001493152-24-019974.md) | [2.3](/filings/0001493152-24-032372.md) | [3.3](/filings/0001493152-24-046022.md) | [3.3 d](/filings/0001493152-26-012801.md) | [3.2](/filings/0001493152-26-023180.md) | [3.2](/filings/0001193125-26-349608.md) | [4.6](/filings/0001493152-25-022401.md) | [6.2 d](/filings/0001493152-26-012801.md) | [6.1](/filings/0001493152-26-023180.md) | [5.4](/filings/0001193125-26-349608.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(18.4)](/filings/0001493152-24-046022.md) | [(18.8) d](/filings/0001641172-25-001826.md) | [(21.6)](/filings/0001493152-25-022401.md) | [(23.7)](/filings/0001493152-25-022401.md) | [(29.8)](/filings/0001493152-25-022401.md) | [(36.7) d](/filings/0001493152-26-012801.md) | [(37.0)](/filings/0001193125-26-349608.md) | [(45.3)](/filings/0001193125-26-349608.md) | [(43.8)](/filings/0001493152-25-022401.md) | [(51.0) d](/filings/0001493152-26-012801.md) | [(52.8)](/filings/0001193125-26-349608.md) | [(78.9)](/filings/0001193125-26-349608.md) |
| Diluted EPS | $ per share | [(0.83)](/filings/0001493152-24-046022.md) | not reported | [(0.64)](/filings/0001641172-25-011053.md) | [(0.62)](/filings/0001641172-25-024148.md) | [(0.70)](/filings/0001493152-25-022401.md) | not reported | [(0.86)](/filings/0001493152-26-023180.md) | [(1.04)](/filings/0001193125-26-349608.md) | [(0.92)](/filings/0001493152-25-022401.md) | not reported | [(0.97)](/filings/0001493152-26-023180.md) | [(1.44)](/filings/0001193125-26-349608.md) |
| Basic EPS | $ per share | [(0.83)](/filings/0001493152-24-046022.md) | not reported | [(0.64)](/filings/0001641172-25-011053.md) | [(0.62)](/filings/0001641172-25-024148.md) | [(0.70)](/filings/0001493152-25-022401.md) | not reported | [(0.86)](/filings/0001493152-26-023180.md) | [(1.04)](/filings/0001193125-26-349608.md) | [(0.92)](/filings/0001493152-25-022401.md) | not reported | [(0.97)](/filings/0001493152-26-023180.md) | [(1.44)](/filings/0001193125-26-349608.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.8](/filings/0001493152-23-040434.md) | [30.7](/filings/0001641172-25-001826.md) | [31.2](/filings/0001493152-24-019974.md) | [30.5](/filings/0001493152-24-032372.md) | [12.6](/filings/0001493152-24-046022.md) | [22.5](/filings/0001493152-26-012801.md) | [16.5](/filings/0001641172-25-011053.md) | [46.4](/filings/0001641172-25-024148.md) | [74.3](/filings/0001493152-25-022401.md) | [166](/filings/0001193125-26-349608.md) | [145](/filings/0001493152-26-023180.md) | [182](/filings/0001193125-26-349608.md) |
| Current assets | $m | [142](/filings/0001493152-23-040434.md) | [191](/filings/0001641172-25-001826.md) | [188](/filings/0001493152-24-019974.md) | [292](/filings/0001493152-24-032372.md) | [272](/filings/0001493152-24-046022.md) | [245](/filings/0001493152-26-012801.md) | [218](/filings/0001641172-25-011053.md) | [183](/filings/0001641172-25-024148.md) | [475](/filings/0001493152-25-022401.md) | [466](/filings/0001193125-26-349608.md) | [409](/filings/0001493152-26-023180.md) | [776](/filings/0001193125-26-349608.md) |
| Total assets | $m | [142](/filings/0001493152-23-040434.md) | [191](/filings/0001641172-25-001826.md) | [188](/filings/0001493152-24-019974.md) | [293](/filings/0001493152-24-032372.md) | [273](/filings/0001493152-24-046022.md) | [245](/filings/0001493152-26-012801.md) | [218](/filings/0001641172-25-011053.md) | [184](/filings/0001641172-25-024148.md) | [476](/filings/0001493152-25-022401.md) | [467](/filings/0001193125-26-349608.md) | [410](/filings/0001493152-26-023180.md) | [828](/filings/0001193125-26-349608.md) |
| Current liabilities | $m | [12.7](/filings/0001493152-23-040434.md) | [14.2](/filings/0001641172-25-001826.md) | [16.7](/filings/0001493152-24-019974.md) | [19.5](/filings/0001493152-24-032372.md) | [26.3](/filings/0001493152-24-046022.md) | [31.7](/filings/0001493152-26-012801.md) | [32.9](/filings/0001641172-25-011053.md) | [39.9](/filings/0001641172-25-024148.md) | [38.8](/filings/0001493152-25-022401.md) | [44.2](/filings/0001193125-26-349608.md) | [33.2](/filings/0001493152-26-023180.md) | [86.9](/filings/0001193125-26-349608.md) |
| Total liabilities | $m | [49.5](/filings/0001493152-23-040434.md) | [51.5](/filings/0001641172-25-001826.md) | [54.4](/filings/0001493152-24-019974.md) | [116](/filings/0001493152-24-032372.md) | [123](/filings/0001493152-24-046022.md) | [130](/filings/0001493152-26-012801.md) | [131](/filings/0001641172-25-011053.md) | [139](/filings/0001641172-25-024148.md) | [359](/filings/0001493152-25-022401.md) | [366](/filings/0001193125-26-349608.md) | [357](/filings/0001493152-26-023180.md) | [841](/filings/0001193125-26-349608.md) |
| Long-term debt | $m | [37.1](/filings/0001493152-23-040434.md) | [37.6](/filings/0001493152-24-011549.md) | [38.0](/filings/0001493152-24-019974.md) | [105](/filings/0001493152-24-032372.md) | [105](/filings/0001493152-24-046022.md) | [105](/filings/0001641172-25-001826.md) | [105](/filings/0001641172-25-011053.md) | [106](/filings/0001641172-25-024148.md) | [137](/filings/0001493152-25-022401.md) | [138](/filings/0001493152-26-012801.md) | [138](/filings/0001493152-26-023180.md) | [0.0](/filings/0001193125-26-349608.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [92.9](/filings/0001493152-24-046022.md) | [140](/filings/0001493152-26-012801.md) | [134](/filings/0001493152-25-022401.md) | [177](/filings/0001493152-25-022401.md) | [150](/filings/0001493152-25-022401.md) | [116](/filings/0001193125-26-349608.md) | [86.7](/filings/0001193125-26-349608.md) | [44.4](/filings/0001193125-26-349608.md) | [117](/filings/0001493152-25-022401.md) | [101](/filings/0001193125-26-349608.md) | [53.5](/filings/0001193125-26-349608.md) | [(12.8)](/filings/0001193125-26-349608.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.7) d](/filings/0001493152-24-046022.md) | [(18.5) d](/filings/0001641172-25-001826.md) | [(17.1)](/filings/0001641172-25-011053.md) | [(18.1) d](/filings/0001641172-25-024148.md) | [(20.6) d](/filings/0001493152-25-022401.md) | [(27.8) d](/filings/0001493152-26-012801.md) | [(35.9)](/filings/0001493152-26-023180.md) | [(36.2) d](/filings/0001193125-26-349608.md) | [(44.8) d](/filings/0001493152-25-022401.md) | [(36.4) d](/filings/0001493152-26-012801.md) | [(55.1)](/filings/0001493152-26-023180.md) | [(55.4) d](/filings/0001193125-26-349608.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001493152-24-046022.md) | [0.0 d](/filings/0001641172-25-001826.md) | [0.1](/filings/0001641172-25-011053.md) | [0.1 d](/filings/0001641172-25-024148.md) | [0.1 d](/filings/0001493152-25-022401.md) | [0.0 d](/filings/0001493152-26-012801.md) | [0.1](/filings/0001493152-26-023180.md) | [0.0 d](/filings/0001193125-26-349608.md) | [0.1 d](/filings/0001493152-25-022401.md) | [0.1 d](/filings/0001493152-26-012801.md) | [0.2](/filings/0001493152-26-023180.md) | [0.1 d](/filings/0001193125-26-349608.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.9](/filings/0001493152-23-040434.md) | [21.7](/filings/0001493152-24-019974.md) | [22.0](/filings/0001493152-24-032372.md) | [22.1](/filings/0001493152-24-046022.md) | [33.6](/filings/0001641172-25-011053.md) | [38.4](/filings/0001641172-25-024148.md) | [42.8](/filings/0001493152-25-022401.md) | [43.1](/filings/0001493152-26-023180.md) | [43.7](/filings/0001193125-26-349608.md) | [47.6](/filings/0001493152-25-022401.md) | [54.5](/filings/0001493152-26-023180.md) | [54.8](/filings/0001193125-26-349608.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,931,908 at 2026-08-05, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349608.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.